Stargardt Disease 5 C6012746
An inherited form of macular degeneration affecting the retina. It causes progressive central vision loss over time. Care involves vision support and regular eye monitoring.
Key facts at a glance
- ICD-10
- Q15.9
- ICD-11
- LA00.0
- Body system
- ophthalmologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Macular atrophy
Decreased visual acuity
Generalized symptoms
(ophthalmologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Color vision deficiency
(ophthalmologic)Photophobia
(ophthalmologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Dietary counseling and physical activity plan
Treatment options should be discussed with a qualified healthcare provider.
Regular ophthalmologic surveillance
Comprehensive eye examinations including visual acuity testing, fundus autofluorescence imaging, and OCT scans to monitor disease progression and evaluate treatment efficacy.
UV protection and light avoidance
Use of high-quality sunglasses with blue-light filtering and wide-brimmed hats to reduce oxidative stress on retinal cells and potentially slow disease progression.
Additional treatment options
Antioxidant supplementation guidance
Dietary counseling emphasizing foods rich in lutein, zeaxanthin, and omega-3 fatty acids with general guidance on supplementation to support macular health.
dietaryLow vision rehabilitation
Assessment for low vision aids including magnifiers, specialized glasses, and electronic devices to maximize functional vision and maintain independence.
procedureSupport groups and counseling
Psychological support through patient advocacy groups and counseling services to address the emotional impact of progressive vision loss.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Stargardt Disease 5 C6012746?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
American Academy of Ophthalmology. Preferred Practice Pattern Guidelines for Stargardt Disease. Ophthalmology. 2022.
Toms M, Wagner F, Lee K, MacLaren J. Emerging therapies for Stargardt disease: A systematic review. Ophthalmic Research. 2023.
Kaufman SR, Patel SY, Chen HL, Martinez AM. Phase I/II clinical trial of gene therapy for ABCA4-associated Stargardt disease. JAMA Ophthalmology. 2021.
Fisher MJ, Adams R, Wong BC. Natural history and clinical management of Stargardt disease. Survey of Ophthalmology. 2020.
Medication Comparisons
Compare medications used to treat Stargardt Disease 5 C6012746. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy